<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508064</url>
  </required_header>
  <id_info>
    <org_study_id>206288</org_study_id>
    <secondary_id>AI438-054</secondary_id>
    <nct_id>NCT02508064</nct_id>
  </id_info>
  <brief_title>Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet</brief_title>
  <official_title>A Two-Part Study to Evaluate the Bioavailability of BMS-626529 Administered as Prodrug BMS-663068 From Prototype Low-Dose Extended-Release Tablets (Part 1) and Prototype Multi-Particulate Formulations (Part 2) Relative to the 600 mg Extended Release Tablet in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part study will determine the bioavailability of BMS-626529 in healthy subjects from
      prototype low dose extended release formulations (Part 1) of BMS-663068 and prototype
      extended release multi-particulate formulations (Part 2) of BMS-663068 relative to 600 mg
      extended release tablet of BMS-663068.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2015</start_date>
  <completion_date type="Actual">November 5, 2015</completion_date>
  <primary_completion_date type="Actual">November 5, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of BMS-626529</measure>
    <time_frame>Day 1 to Day 4 of each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) of BMS-626529</measure>
    <time_frame>Day 1 to Day 4 of each period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-626529</measure>
    <time_frame>Day 1 to Day 4 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of BMS-663068 will be measured by incidence of Adverse events (AEs), Serious adverse events (SAEs), and AEs leading to discontinuation;, and results of clinical laboratory tests, vital signs, 12-lead ECGs, and Physical examination (PE)</measure>
    <time_frame>Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of BMS-663068 will be measured by incidence of AEs, SAEs, and AEs leading to discontinuation; and results of clinical laboratory tests, vital signs and 12-lead ECGs</measure>
    <time_frame>Day 1 to Day 4 of each period; for SAEs up to 30 days post discontinuation of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 1 × 600 mg extended-release (ER) tablet formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Prototype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Prototype 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Prototype 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Prototype 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Prototype 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 1 × 600 mg ER tablet formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Prototype 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Prototype 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Prototype 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Prototype 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Part 2: Prototype 2</arm_group_label>
    <arm_group_label>Part 1: Prototype 2</arm_group_label>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 1: Prototype 5</arm_group_label>
    <arm_group_label>Part 1: Prototype 4</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 2: Prototype 1</arm_group_label>
    <arm_group_label>Part 1: Prototype 3</arm_group_label>
    <arm_group_label>Part 2: Prototype 4</arm_group_label>
    <arm_group_label>Part 1: Prototype 1</arm_group_label>
    <arm_group_label>Part 2: Prototype 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Males and females, 18 to 50 years of age, inclusive

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical and surgical history, PE findings, vital sign measurements, 12-lead ECG
             measurements, physical measurements, and clinical laboratory test results

          -  Women of childbearing potential (WOCBP) must have a negative urine pregnancy test
             (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human
             chorionic gonadotropin) within 24 hours prior to the start of study drug

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             PE, vital signs, ECG, or clinical laboratory determinations beyond what is consistent
             with the target population

          -  Any of the following on 12-lead ECG prior to study drug administration, confirmed by
             repeat:

             i) PR ≥ 210 msec ii) QRS ≥ 120 msec iii) QT ≥ 500 msec and iv) QTcF ≥ 450 msec

          -  Exposure to any investigational drug or placebo within 12 weeks of study drug
             administration

          -  Positive blood screen for hepatitis C antibody (HCV Ab), hepatitis B surface antigen
             (HBsAg), or HIV-1 and HIV-2 antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

